## **ICICI Prudential Healthcare ETF**

(An open-ended Index Exchange Traded Fund tracking Nifty Healthcare Index)

**Returns of ICICI Prudential Healthcare ETF - Growth Option as on December 31, 2021** 

Particulars	6 Months	1 Year	3 Years	5 Years	Since inception
	Simple Annualized Returns (%)	CAGR (%)	CAGR (%)	CAGR (%)	CAGR (%)
Scheme	4.54	-	-	-	-
Nifty Healthcare TRI (Benchmark)	4.70	-	-	-	-
Nifty 50 TRI (Additional Benchmark)	21.67	-	-	-	-
NAV (Rs.) Per Unit (as on December 31,2021 : 89.7678)	87.76	-	-	-	-

Simple annualized returns have been provided as per the extant guidelines since the scheme has completed 6 months but not 1 year. However, such returns may not be representative. Absolute returns of the Scheme for the 6 month period is 2.29%.

Notes:

1. Different plans shall have different expense structure. The performance details provided herein are of ICICI Prudential Healthcare ETF. 2. The scheme is currently managed by Kayzad Eghlim & Nishit Patel. Mr. Kayzad Eghlim has been managing this fund since May 2021. Total Schemes managed by the Fund Manager is 26 (26 are jointly managed). Mr. Nishit Patel has been managing this fund since May 2021. Total Schemes managed by the Fund Manager is 26 (26 are jointly managed). Mr. Nishit Patel has been managing this fund since May 2021. Total Schemes managed by the Fund Manager is 26 (26 are jointly managed). Mr. Nishit Patel has been managing this fund since May 2021. Total Schemes managed by the Fund Manager is 26 (26 are jointly managed). Mr. Nishit Patel has been managing this fund since May 2021. Total Schemes managed by the fund managers.

3. Date of inception: 18-May-21.

4. Past performance may or may not be sustained in future and the same may not necessarily provide the basis for comparison with other investment.

5. Load is not considered for computation of returns.

Short Term Debt and net current assets

**Total Net Assets** 

Top Ten Holdings

6. In case, the start/end date of the concerned period is a nonbusiness date (NBD), the NAV of the previous date is considered for computation of returns. The NAV per unit shown in the table is as on the start date of the said period 7. NAV is adjusted to the extent of IDCW declared for computation of returns.

8. The performance of the scheme is benchmarked to the Total Return variant of the Index.

		Fund Details		
Fund Managers** : Mr. Kayzad Eghlim (Managing this fund since May 2021 & Overall 29 Years of experience)		Monthly AAUM as on 31-Dec-21 : Rs. 95.66 crores Closing AUM as on 31-Dec-21 : Rs. 103.87 crores	Exit load for Redemption / Switch out :- Lumpsum Investment Option Nil	
Nishit Patel (Managing this fund since May, 2021 & Overall 3 years of experience)		Minimum application amount for buy/sale of units: Through NSE and BSE - One Unit and in multiples thereof. Directly with AMC - Units are to be purchased in creation unit size	Exchange Listed on: Codes & Symbols: NSE and BSE NSE : ICICIPHARM BSE : ICICIPHARM	
Indicative Investment Horizon: 5 years and above	₹ 	i.e 50,000 units and in multiples thereof.(w.e.f 25 May 2021)	ISIN : INF109KC1Q72	
Inception/Allotment date: 18-May-21		NAV (As on 31-Dec-21): Rs. 89.7678	Total Expense Ratio @@ : Other : 0.15% p. a.	
Portfolio	as on D	ecember 31, 2021	Benchmark	
Company/Issuer		% to NAV	NIFTY Healthcare Index	
Equity Shares		99.99%	Quantitative Indicators	
Healthcare Services		14.30%	Average P/E : Average P/B : Average Dividend Yield :	
<ul> <li>Apollo Hospitals Enterprise Ltd.</li> </ul>		10.07%	Average P/E : Average P/B : Dividend Yield : 42.63 8.34 0.53	
Dr Lal Pathlabs Ltd.		2.48%	42.03 0.34 0.55	
Metropolis Healthcare Ltd.		1.75%	Annual Portfolio Turnover Ratio :	
Pharmaceuticals		83.20%	Equity - 1.03 times	
<ul> <li>Sun Pharmaceutical Industries Ltd.</li> </ul>		18.22%		
<ul> <li>Divi's Laboratories Ltd.</li> </ul>		11.89%	Note : - "Portfolio Beta, Standard Deviation, R Squared, Sharpe Ratio and Track Error of the Scheme is not computed owing to the short time frame since launch	
<ul> <li>Dr. Reddy's Laboratories Ltd.</li> </ul>		11.89%	the Scheme." The figures are not netted for derivative transactions. Refer Disclaimer of NSE Indices Limited (NSE Indices) on page no. 140. @@ Total Expense Ratio is as on the last business day of the month.	
Cipla Ltd.		9.73%		
Lupin Ltd.		4.57%		
Laurus Labs Ltd.		4.21%	To Refer to the annexure for details on scheme objective, IDCW history and SIP details Click here	
Aurobindo Pharma Ltd.		4.12%		
Biocon Ltd.		3.40%		
Alkem Laboratories Ltd.		3.37%		
Torrent Pharmaceuticals Ltd.		3.21%		
IPCA Laboratories Ltd.		2.96%		
Cadila Healthcare Ltd.		2.47%		
Glenmark Pharmaceuticals Ltd.		1.58%		
Pfizer Ltd.		1.57% <b>2.49</b> %	Riskometer	
Equity less than 1% of corpus Short Term Debt and net current assets		2.49% 0.01%	This product labelling is applicable only to the scheme	

0.01%

100.00%

This Product is suitable for investors who are seeking\*:

tors understand that their principa

will be at Very High risk

product is suitable for them

tracking error. Scheme

An Exchange Traded Fund that aims to provide returns that closely correspond to the returns provided by Nifty Healthcare Index, subject to traditionary and the second seco

\*Investors should consult their financial advisers if in doubt about whether the

Benchmark (Nifty Healthcare TRI)

Benchmark riskometer is at Verv High risk.

Securities and the corresponding derivative exposure with less than 1% to NAV, have been clubbed together with a consolidated limit of 10%.

ICICI Prudential Mutual Fund Corporate Office ONE BKC, A - Wing, 13th Floor, Bandra-Kurla Complex, Mumbai 400 051, India. Tel: 022 - 26525000 Fax: 022 - 26528100, website: www.icicipruamc.com, email id: enquiry@icicipruamc.com

## **Statutory Details & Risk Factors**

## Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

**Disclaimer:** In the preparation of the material contained in this document, the Asset Management Company (AMC) has used information that is publicly available, including information developed in-house. Some of the material used in the document may have been obtained from members/persons other than the AMC and/or its affiliates and which may have been made available to the AMC and/or to its affiliates. Information gathered and material used in this document is believed to be from reliable sources. The AMC however does not warrant the accuracy, reasonableness and / or completeness of any information. We have included statements / opinions / recommendations in this document, which contain words, or phrases such as "will", "expect", "should", "believe" and similar expressions or variations of such expressions that are "forward looking statements". Actual results may differ materially from those suggested by the forward looking statements due to risk or uncertainties associated with our expectations with respect to, but not limited to, exposure to market risks, general economic and political conditions in India and other countries globally, which have an impact on our services and / or investments, the monetary and interest policies of India, inflation, deflation, unanticipated turbulence in interest rates, foreign exchange rates, equity prices or other rates or prices etc.

The AMC (including its affiliates), the Mutual Fund, the trust and any of its officers, directors, personnel and employees, shall not be liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner. The recipient alone shall be fully responsible/are liable for any decision taken on this material.